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Physicochemical parametersAbstract The chemical class of benzopyrones consists of a large number of compounds possessing
the benzene ring fused with the oxygen containing pyrone ring. This class is further divided into the
benzo-c-pyrone i.e. ﬂavonoids and the benzo-a-pyrone i.e. coumarins. Coumarins, the 2H-chromen-
2-one and its related analogues exhibit a multitude of biological activities. Attempts made in the
continuous chemical diversiﬁcation of this parent nucleus have brought signiﬁcant alterations in
the biological activity among the generated compounds and therefore, this category of benzopyro-
nes has been much exploited in the current medicinal chemistry research. Thus, it was thought
worthwhile to present a review on the newly synthesised heterocyclic coumarinyl derivatives with
their physicochemical parameters and biological activity, attempted by our co-workers. This review
also creates a platform for highlighting approaches and strategies used in the chemical synthesis of
coumarinyl compounds along with their biological activity relating to their structure.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Coumarin and its related analogues are found to occur naturally
as secondary metabolites in higher plants (Curir et al., 2007 and
Lee, 2004) and also in micro-organisms (Xu et al., 2009). Simple
compounds belonging to this chemical class, for instance 7-
hydroxy coumarin (Fylaktakidou et al., 2004) and 4-hydroxy
coumarin (Jung and Park, 2009) have been used as a backbone
to attain chemically and biologically diverse agents. Some of the
extensions made on the parent coumarin have generated newer
chemical compounds which act against various targets like bac-
terial DNA gyrase (Musicki et al., 2003) and topoisomerase
(Peng and Marians, 1993), monoamine oxidase (Chimenti
et al., 2009), acetylcholinesterase (Anand et al., 2012), TNF-a
(NNoolvi et al., 2011), IL-6 (Upadhyay et al., 2011), ROS path-
way (Beillerot et al., 2008), macrophage migration inhibitory
factor (MIF) (Orita et al., 2001), casein kinase 2 (CK2) (Chilin
et al., 2008), serine protease (Pochet et al., 1996), tyrosinase
(Fais et al., 2009), 5a-reductase (Fan et al., 2001), 17b-hydroxy-
steroid dehydrogenase type-1, oxidoreductase, cyclooxygenase
and lipoxygenase (Geronikaki et al., 2008). In recent years,
many structural modiﬁcations have been attempted at various
positions of the coumarin ring system, Fig. A.1, (Anand et al.,
2012; Beillerot et al., 2008 and Chilin et al., 2008) for example,
at the 2nd position (Liu et al., 2006), 3rd position (Musa et al.,
2011;Nikhilet al., 2012 and Sashidhara et al., 2011), 4th position
(Jung and Park, 2009), 5th position (Noolvi et al., 2011), 6th
position (Starcevic et al., 2011), 7th position (Manojkumar
et al., 2009) and the 8th position (Eissa et al., 2009). Some of
the other modiﬁcations include, formation of coumarinyl metal
complexes (Kostova and Momekov, 2006), synthesis of thio-
coumarin (Kumar et al., 2005 and Reddy et al., 2005) and imi-
nocoumarin analogues (Gorobets et al., 2002). Moreover, theincrease in the number of coumarin derivatives synthesised
and screened for biological activity hasmade it essential to study
compounds under this chemical class as, such scaffolds possess
signiﬁcant therapeutic potentials. Thus, in this review we focus
on some of the modiﬁcations attempted on the coumarin ring
by our team over a period of time and discuss various synthetic
approaches, physicochemical parameters and biological activity
studies.
2. Synthesis of coumarin analogues
Coumarin and its related derivatives have been well reported to
be synthesised via various mechanisms involved in reactions
such as Claisen rearrangement (Ghantwal and Samant, 1999),
Perkin reaction (Majumder and Majumder, 1993), Pechmann
reaction (Upadhyay et al., 2008), Witting reaction (Harayama
et al., 1994), Knoevenagel condensation (Shaabani et al.,
2009) and Baylis–Hillman Reaction (Musa, 2002). In recent
years, attempts have been made to prepare coumarinyl deriva-
tives by other alternative methods such as solid phase synthesis
(Liu et al., 2006), microwave irradiation (Kidwai et al., 2004)
and ultrasonication (Di Cuollo et al., 1965). Further, the synthe-
sis of coumarin hybrid with resveratrol (Fais et al., 2009) and
estrogen (Musa et al., 2009) was among some of the strategies
applied to arrive at potential therapeutic agents. In this review,
we summarise various approaches used for the synthesis of
different conjugated coumarin-heterocyclic ring systems by
our team.
2.1. Combination of thiazole ring and coumarin nucleus
Thiazoles have been extensively used in various chemical reac-
tions as a parent, substituent as well as an intermediate
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for the synthesis of various thiazolyl coumarin derivatives
(Arshad et al., 2011). The present review highlights the synthe-
sis of various carboxamides and Schiff’s bases of thiazolyl
coumarin. A series of carboxamide derivatives of 20-amino-
40-(6-bromo-3-coumarinyl) thiazole 1 showing analgesic and
anti-inﬂammatory activities were reported (Venugopala and
Jayashree, 2003), Fig. A.2, Table B.1. Title compounds 2–3
were obtained by treating the parent amine 1 with different
aromatic acid chlorides in pyridine medium and the acetyl
derivative of 1 was prepared by treating the same with acetyl
chloride. Parent amine 1 was prepared by the reaction between
3-bromoacetyl-6-bromocoumarin and thiourea. The former
was prepared by bromination of 3-acetyl-6-bromocoumarin
in alcohol free chloroform. 3-acetyl-6-bromocoumarin was
prepared by mixing appropriate molar quantities of 5-bromo-
salicyaldehyde and ethylacetoacetate in the presence of piperi-
dine as a catalyst. Further, three series of substituted Schiff’s
bases of aminothiazolyl coumarins were prepared and screened
for their analgesic and anti-inﬂammatory activities, Figs. A.3–
5, Table B.1. Schiff’s bases of aminothiazolyl coumarin 7–9
(Jayashree et al., 2004), aminothiazolyl bromocoumarin
10a–m (Venugopala and Jayashree, 2004) and aminothiazolyl
chlorocoumarin 12–14 (Jayashree et al., 2005a,b), were syn-
thesised by reﬂuxing 20-amino-40-(3-coumarinyl) thiazole 6,
20-amino-40-(6-bromo-3-coumarinyl) thiazole 1 and 20-amino-
40-(6-chloro-3-coumarinyl) thiazole 11 with different aldehydes
in absolute ethanol as medium, respectively. Parent amines,
such as compounds 6, 1 and 11 were prepared by cyclising
3-acetylbromo-6H-coumarins 5, 3-bromoacetyl-6-bromocou-
marin and 3-bromoacetyl-6-chlorocoumarin with thiourea,
respectively. Bromination of 3-acetylcoumarin 4 (Munshi
et al., 2004) in alcohol free chloroform yielded the compound
5. 3-acetylcoumarin 4 was prepared by mixing appropriate
molar quantities of salicylaldehyde and ethylacetoacetate in
the presence of piperidine as catalyst. Further, the variation
in reaction time with respect to different substituents for for-
mation of compounds belonging to the series 10a–m was also
reported (Venugopala and Jayashree, 2004). It was observed
that, the order of reactivity of reactants when correlated with
the reaction time required for product formation is given as;
10i at lowest (60 min) < 10b, 10f and 10k (90 min) < 10a,
10c, 10d, 10g, 10h, 10j, 10l and 10m (120 min) < 10e (150 min).
In addition to this, the synthesis of some of the Schiff’s
bases of aminothiazolyl bromocoumarin 10a–m was also
attempted by microwave irradiation on 20-amino-40-(6-
bromo-3-coumarinyl) thiazole 1 with substituted aromatic
aldehydes in absolute ethanol at different time intervals
(Venugopala and Jayashree, 2008). This method served as an
alternative method for enhancing the rate and efﬁciency of
the reaction. Further, comparison of the rate of product for-
mation for all three methods namely, the conventional reﬂux-
ing method (method A), conventional heating method (method
B) and microwave-induced organic reaction enhancement
method (MORE, method C) was done. It was found that,
products were formed within 65–113 s at 260 W in case of
method C when compared with method A and method B,
illustrating the efﬁciency of microwave technique over conven-
tional techniques.
Moreover, synthesis of substituted 20-arylamino-40-(3-cou-
marinyl) thiazoles and 20-arylamino-40-(6-bromo-3-coumari-
nyl) thiazoles, 17a–u was also performed by condensation of3-bromoacetylcoumarin with thiourea and substituted phen-
ylthioureas (Venugopala et al., 2004), respectively, Fig. A.6,
Table B.1. Initially, substituted salicylaldehydes were reacted
with ethylacetoacetate in the presence of piperidine, to give
3-acetyl-6-H/bromocoumarins 5, 15, respectively. These on
reaction with bromine in alcohol free chloroform yielded the
respective 3-bromoacetyl-6-bromocoumarin 16.
2.2. Combination of triazole-thiadizine ring and coumarin
nucleus
Triazoles such as 1, 2, 4-triazole have been reported for various
pharmacological activities like anti-bacterial (Bhat et al.,
2001), anti-viral and anti-fungal (Al-Masoudi et al., 2006). A
few triazolyl coumarins have been reported so far along with
their biological activities (Shi and Zhou, 2011). Further, some
thiaziadinyl coumarins possessing biological activity were also
reported (Rao and Reddy, 2009). It was thought worthwhile to
bring linkers on the existing coumarin nucleus with other het-
erocyclic system and in our studies we have tried using triazole-
thiadiazinyl ring system, Fig. A.7, Table B.1. A series of novel
triazolo-thiadiazinyl bromocoumarin derivatives 18a–k
(Jayashree et al., 2005a,b), triazolo-thiadiazinyl chlorocouma-
rins 19a–k (Jayashree et al., 2006) and triazolo-thiadiazinyl
coumarins 20a–l (Jayashree et al., 2007) were prepared and
reported. Here, substituted triazole and 3-bromoacetyl-6-bro-
mocoumarin 16, 3-bromoacetyl-6-chlorocoumarin and 3-ace-
tylbromo-6H-coumarins 5 were reﬂuxed with dimethyl
formamide in absolute ethanol medium and catalytic pyridine
for about 120 min, respectively, to yield title compounds. For
the synthesis of 1, 2, 4-triazoles, substituted aromatic acids
were converted to their corresponding methyl esters, acid
hydrazides, potassium dithiocarbamate salts as intermediates.
2.3. Preparation of coumarinyl chalcones
Chalcones or 1, 3-diaryl-2-propen-1-ones consist of open-chain
ﬂavonoids in which two aromatic rings are joined by a three-
carbon a, b-unsaturated carbonyl system. Various substituted
natural and synthetic chalcones have shown to exhibit signiﬁ-
cant pharmacological potential (Sahu et al., 2012). In our
research, coumarinyl chalcones were prepared and screened
for anti-bacterial activity, as shown in Fig. A.8, Table B.1.
They were also used as intermediates for further synthesis of
other test compounds. Synthesis of coumarinyl chalcones
was undertaken by means of both conventional as well as
microwave method (Jayashree et al., 2008). Title compounds
21–22 were obtained by reﬂuxing as well as by microwave irra-
diation of substituted 6-(H/chloro/bromo) acetylcoumarins
and different aromatic aldehydes with ethanol in the presence
of piperidine. Different 6-(substituted) acetylcoumarins
(Chopra et al., 2006) were synthesised by means of Pechmann
reaction, involving the reaction of 5-(substituted) salicylalde-
hydes with ethylacetoacetate in the presence of piperidine, at
freezing temperature for 120–180 min. The application of
microwave energy to achieve coumarinyl chalcones signiﬁ-
cantly reduced the reaction time from 420 min of reﬂux to 2–
3 min of microwave heating along with improved product
yield.
On the contrary, preparation of some novel coumarinyl
chalcones 23a–f was achieved by reaction between 3-(substi-
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the presence of 30% ethanolic sodium hydroxide (Jayashree
et al., 2009).
2.4. Combination of pyrazoline ring and coumarin nucleus
Substituted pyrazolines have been extensively reviewed for a
range of biological activities (Shaaban et al., 2012). Pyrazolinyl
coumarins have also been synthesised and reported for their
biological activities (Khode et al., 2009). Synthesis of some
of the 5-(substituted phenyl)-1-phenyl (2-pyrozoline-300-yl)
substituted coumarins was attempted (Jayashree et al., 2008),
as shown in Fig. A.9, Table B.1. The title compounds 24–25
were achieved by reﬂuxing different substituted coumarinyl
chalcones 21–22 with phenyl hydrazine in the presence of
piperidine as catalyst in ethanol for about 600 min approxi-
mately equivalent to 10 h of conventional heating.
2.5. Combination of pyridine ring and quinoline with coumarin
nucleus
Pyridine fused coumarins have been synthesised and tested for
biological activities such as anti-cholinesterase and anti-micro-
bial (Alipour et al., 2012). We reported the synthesis of some
of the useful heterocyclic substitutions on coumarin with pyr-
idine and quinoline, Fig. A.10, Table B.1. 3-coumarinoyl
pyridinium bromides 26a–l and 3-coumarinoyl quinolinium
bromides 27a–c were prepared by 2 h of reﬂuxing followed
by reaction at room temperature for 4–5 h in the presence of
dry toluene between 3-bromoacetylcoumarins and methyl
and ethyl esters of nicotinic acid and isonicotinic acid to give
26a–l and with quinoline to give 27a–c (Porwal et al., 2010).
Also, preparation of a series of substituted pyridinyl couma-
rins 28a–g was reported (Jayashree et al., 2010). Few of the
compounds from the synthesised 26a–l series were taken in gla-
cial acetic acid and ammonium acetate and reﬂuxed at 130 C
for 6 h with different chalcones to obtain 7 derivatives of
pyridinyl coumarins 28a–g.
2.6. Other substituted coumarin analogues
Synthesis of novel coumarin analogues such as 29–32 was also
carried out (Jayashree et al., 2011), as shown in Fig. A.11,
Table B.1. Analogues such as 29a–b, 31a–b and 32a–b were
obtained by benzoylation of coumarins using different acid
chlorides in dry pyridine as catalyst. The parent coumarins
were obtained by reaction of different substituted resorcinols
with redistilled ethylacetoacetate in the presence of concen-
trated sulphuric acid, initially for 2 h at low temperatures
but later maintained at room temperature for 18 h. Carboxam-
ide analogues 30a–b were obtained by reacting amino couma-
rin with 5-amino salicylic acid. Amino coumarin was prepared
by conversion of 6-nitro-3-acetylcoumarin in aqueous ammo-
nia solution by aqueous sodium hydrosulﬁte, at boiling tem-
perature for 15 min. The former was prepared by treating 5-
nitrosalisaldehyde and ethylacetoacetate in absolute alcohol
in the presence of catalytic piperidine.
Alternatively, an attempt was made to generate function-
ally diverse coumarins with the help of microbiology tech-
nique, namely biotransformation (Das and Rosazza, 2006).
Here, instead of using the conventional synthetic route forobtaining coumarin, it was thought to undertake certain func-
tional group modiﬁcations/bioconversions of simple coumarin
substrates using micro-organisms. As a result, experiments on
the microbial biotransformation of some of the hydroxy and
ethoxy substituted coumarins were performed using different
bacterial and fungal strains. The microbial biotransformation
of hydroxy and ethoxy substituted coumarin substrates under
suitable fermentation conditions, led to their successful bio-
conversion into methoxy and hydroxy substituted coumarin
derivatives, respectively (Nigam et al., 2013).
3. Biological activity
A wide range of substituted coumarins are reported to possess
anti-protozoal (Oketch-Rabah et al., 1997), anti-fungal (Al-
Amiery et al., 2012), anti-bacterial (Manojkumar et al.,
2009), anti-Parkinsonism (Binda et al., 2007), anti-Alzheimer’s
(Anand et al., 2012), anti-pyretic, analgesic and anti-inﬂamma-
tory (Eissa et al., 2009), anti-oxidant (Beillerot et al., 2008),
anti-coagulant (Jung and Park, 2009), anti-depressant
(Sashidhara et al., 2011), anti-HIV (Kostova et al., 2006),
anti-tuberculosis (Upadhyay et al., 2011), anti-viral (Neyts
et al., 2009) and anti-cancer activities (Devji et al., 2011). Het-
erocyclic systems substituted on coumarin at the 3rd position
have also shown promising biological activities (Nikhil et al.,
2012). Here, work carried out on such systems with their bio-
logical applications has been presented.
3.1. Analgesic and anti-inﬂammatory
The analgesic and anti-inﬂammatory activities of synthesised
test compounds were evaluated in in vivomodels using the acetic
acid-induced abdominal constriction method (Collier et al.,
1968) and the carrageenan induced rat hind paw oedema
method (Kulkarni et al., 1986). Series of carboxamides of 20-
amino-40-(6-bromo-3-coumarinyl) thiazole 1–3, were screened
for analgesic and anti-inﬂammatory activities (Venugopala
and Jayashree, 2003). Among all carboxamide derivatives
tested, it was found that compounds bearing substitutions at
meta, ortho and para positions such as 2c, 2e and 2h showed
analgesic activity at 41.66%better than that of the standard ace-
tylsalicylic acid at 37.45%. The effect of the nitro group on the
analgesic activity wasmore pronounced atmeta position among
all derivatives screened. Whereas, compounds bearing chloro
and bromo substitutions were found to bemore effective as anal-
gesics, when substituted at ortho and para positions in 20-amino-
40-(6-bromo-3-coumarinyl) thiazole carboxamides. However,
overall effect of substitutions clearly suggested the order of
increase in analgesic activity with meta> para> ortho position
when compared to that of the parent carboxamide 2a. Further,
test compounds such as 1 and 3 showed analgesic activity at
6.95% and 26.53%, respectively when compared to their car-
boxamide analogues 2a–j at 32.36–41.66%. From this study, it
was clearly understood that, the substituted aryl carboxamide
derivatives of 20-amino-40-(6-bromo-3-coumarinyl) thiazole
weremore potent as analgesics than their counterparts. Alterna-
tively, the anti-inﬂammatory activity of carboxamide deriva-
tives 2a–j was found to be feeble when compared with the
parent compound 1 and carboxamide 3, showing anti-inﬂam-
matory potential at 46.96% and 53.59% respectively against
the standard phenylbutazone at 45.30%. However, among the
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the anti-inﬂammatory activity was found to be relatively better
formeta> para> ortho substituents. Further, compounds with
bromo and chloro substitutions on the meta position such as 2g
and 2j showed activity better than the meta-nitro derivative 2c
and remaining test compounds. It was also found that, the
N-acetyl derivative of carboxamide 3 showed relatively lower
analgesic and anti-inﬂammatory activities when compared with
that of other substituted aryl carboxamide derivatives of
20-amino-40-(6-bromo-3-coumarinyl) thiazole.
Further, when three series Schiff’s bases of 20-amino-40-(3-
coumarinyl) thiazole 6 were screened for analgesic and anti-
inﬂammatory activities (Jayashree et al., 2004; Jayashree et al.,
2005a,b andVenugopala and Jayashree, 2004), it was found that
chloro and bromo substitutions at the 6th position on the parent
aminothiazolyl coumarin 6 enhanced the analgesic potential of
theirSchiff’sbases when comparedwithSchiff’sbases of the par-
ent compound 6. The analgesic activity of Schiff’s bases of 20-
amino-40-(6-H/chloro/bromo-3-coumarinyl) thiazoles was found
to be in the order with 6-chloro substituted 12a–m–14>6-bromo
substituted 10a–m >6-H/unsubstituted 7a–j–9. Further, ﬁnd-
ings also revealed for the improvement in the analgesic activity
ofSchiff’sbases of 20-amino-40-(6-substituted-3-coumarinyl) thi-
azole presumably because of the retention of different substitu-
ents at ortho, meta and para positions as compared to the 20-
amino-40-(6-H/unsubstituted-3-coumarinyl) thiazole series.
Among the para andmeta di-substitutedSchiff’s bases of amino-
thiazolyl coumarin, the test compound 12f, a di-methoxy deriv-
ative of the parent 20-amino-40-(6-chloro-3-coumarinyl)
thiazole 11 showed analgesic activity better than test compounds
10l and 7f, which were also di-methoxy derivatives, but from 20-
amino-40-(6-bromo-3-coumarinyl) thiazole 1 and 20-amino-40-
(3-coumarinyl) thiazole 6, respectively. Further, the test com-
pounds such as 8–9 and 13–14were found to show feeble analge-
sic activity compared to that of the substituted aryl Schiff’s bases
of aminothiazolyl coumarin. The test compound 12e, showing
more than two-fold activity than that of the standard analgesic,
exhibited maximum analgesic activity among the Schiff’s bases
of aminothiazolyl coumarin, thereby highlighting the effect of
tri-methoxy substitution at ortho, para and meta positions of
the aryl group of 20-amino-40-(6-chloro-3-coumarinyl) thiazole
nucleus. However, the trend observed for the anti-inﬂammatory
activity of the Schiff’s bases of substituted aminothiazolyl cou-
marin was paradoxical. Here, the Schiff’s bases of 20-amino-40-
(6-bromo-3-coumarinyl) thiazole 10a–m were found to be more
active than 6-chloro substituted 12a–m–14 and 6-H/unsubstitut-
ed 7a–j–9 analogues. Further, all the substituted aryl derivatives
of 20-amino-40-(6-bromo-3-coumarinyl) thiazole except, the test
compound 10k, an unsubstituted aryl derivative of the parent,
showed anti-inﬂammatory activity more than that of the stan-
dard phenylbutazone. However, the most active anti-inﬂamma-
tory derivative among all Schiff’s bases of aminothiazolyl
coumarin was found to be the compound 10b, an ortho, para,
meta tri-methoxy aryl derivative of 20-amino-40-(6-bromo-3-cou-
marinyl) thiazole. The screening of anti-inﬂammatory and anal-
gesic activities of different series of synthesised Schiff’s bases of
aminothiazolyl coumarin, clearly illustrated that, the substitu-
tion made with the tri-methoxy group at ortho, meta and para
positions of the aryl Schiff’s bases of 20-amino-40-(6-substi-
tuted-3-coumarinyl) thiazoles as in case of test compounds 10b
and 12e, greatly increased the analgesic as well as anti-inﬂamma-
tory potential of the respective scaffolds. Further, chloro andbromo substitutions at the 6thpositionof the 20-amino-40-(3-cou-
marinyl) thiazole, displayed improved analgesic and anti-inﬂam-
matory activities over their unsubstituted counterparts. Thus,
from variation in response to the analgesic and anti-inﬂamma-
tory activities of these compounds, it was understood that, the
Schiff’s bases of aminothiazolyl coumarin would interact better
with different molecular targets involved in understanding anal-
gesic and anti-inﬂammatory pathways.
In the quest to develop potential NSAIDs, evaluation of
series of substituted 20-arylamino-40-(3-coumarinyl) thiazoles
and 20-arylamino-40-(6-bromo-3-coumarinyl) thiazoles, 17a–u
in terms of analgesic and anti-inﬂammatory activities was done
(Venugopala et al., 2004). It was observed that the substitution
of the bromo group at the 6th position of the 20-arylamino-40-
(3-coumarinyl) thiazoles did not bring any signiﬁcant change
in their analgesic as well as anti-inﬂammatory activities as
compared to the standard ibuprofen at 74% activity and dic-
lofenac sodium at 72.98% activity. Therefore, it was under-
stood that the substituted aryl amino coumarinyl thiazoles
were not effective ligands for these activities. However, from
other studies it was found that, the series of their Schiff’s bases
12a–m–14, 10a–m and 7a–j–9 had proved to be much better
ligands for analgesic and anti-inﬂammatory activities. Few of
the coumarinyl chalcones were also tested for analgesic and
anti-inﬂammatory activities (Jayashree et al., 2009). These
compounds were also randomly subjected to anti-oxidant
activity using the DPPH radical scavenging method but, none
of the compounds exhibited anti-oxidant potential. In con-
trast, among the different 6-(chloro/bromo/H)-aryl substituted
coumarinyl chalcones, test compounds 21k and 21g bearing
chloro and bromo groups on the 6th position of benzopyrone
nucleus were not just equally active as analgesics but were also
highly active at 92.30% activity as compared to both the stan-
dard diclofenac at 74% and 6-H/unsubstituted derivatives 21b
and 22a at 76–78%. However, randomly selected chalcones
screened for anti-inﬂammatory activity did show activity but,
none of the coumarinyl derivatives were nearly active as
anti-inﬂammatory standard ibuprofen at 64.70%. It could be
suggested from the screening of coumarinyl chalcones that
the halogen substitution at the 6th position of benzopyrone
nucleus had a greater inﬂuence on the analgesic activity than
unsubstituted analogues. It can be understood that these chal-
cones may be acting through mutually exclusive molecular
pathways involved for the three activities.
Screening of few of the 5-((substituted phenyl)-1-phenyl-2-
pyrozoline-300-yl)-6-halogen substituted coumarins for analge-
sic and anti-inﬂammatory activities (Jayashree et al., 2008),
such as 24c and 25a both at the 6th position unsubstituted
derivatives, has shown anti-inﬂammatory activity comparable
to the standard aspirin. Moreover, test compounds such as
24c, 24e, 24l and 25a–b exhibited potent analgesic activity as
compared to the standard aspirin. This scaffold of substituted
coumarin consisting of 5-(substituted phenyl)-1-phenyl-2-
pyrozoline-300-yl)-6-halogen could be thereof undertaken for
further modiﬁcations to arrive at potentially active analgesics
and anti-inﬂammatory agents.3.2. Anti-bacterial activity
The evaluation of anti-bacterial activity of substituted couma-
rins synthesised was performed in vitro by measuring the zone
890 B.S. Jayashree et al.of inhibition using the agar diffusion method (Di Cuollo et al.,
1965) and also by measurement of minimum inhibitory con-
centration (MIC) (Ericsson et al., 1960), using two fold dilu-
tions in 96-well plate, against some of the gram positive
strains like Bacillus subtilis and Staphylococcus aureus and
gram negative strains like Escherichia coli, Klebsiella pneumo-
niae and Pseudomonas aeruginosa.
Schiff’s bases of amino thiazolyl bromocoumarins were
tested for anti-bacterial activity against B. subtilis and E. coli
(Venugopala and Jayashree, 2008). The MIC of all test com-
pounds showed promising activity and the compound 10a,
equally active as the standard ampicillin exhibited MIC in
the range of 141–147 lg and the compound 10g exhibited weak
activity at 280 lg when compared to that of the standard ampi-
cillin at 145 lg and 135 lg against B.subtilis and E. coli, respec-
tively. Schiff’s bases of such 20-amino-40-(6-bromothiazolyl
bromo-3-coumarinyl) thiazole may not be suitable candidates
as potent anti-bacterial agents however, there need to be exten-
sive studies on their structural modiﬁcations.
On evaluation of anti-bacterial activity of series of substi-
tuted triazolo-thiadiazinyl coumarin derivatives when studied
against B. subtilis, S. aureus, E. coli, K. pneumoniae and P.
aeruginosa (Jayashree et al., 2005a,b, 2006, 2007), it was found
that, compounds 18i, 19i and 20j bearing the pyridinyl group at
para position of the substituted phenyl ring on the 5th posi-
tion, possessed better anti-bacterial activity among all the
derivatives of 6-bromo/chloro/H substituted series of com-
pounds 18a–k, 19a–k and 20a–l, against all bacterial strains
as compared to the standard amoxicillin and gentamycin.
Alternatively, 2-chlorophenyl derivatives of 6-bromo/chloro/H
substituted 3-(5-(substituted phenyl)-1, 2, 4-triazolo-[3, 4-b]
[1, 3, 4]-thiadiazin-5-yl)-2H-1-benzopyran-2-ones were among
the least active anti-bacterial. However, a clear distinction of
the effect of 6-bromo/chloro/H substituted 3-(5-(substituted
phenyl)-1, 2, 4-triazolo-[3, 4-b] [1, 3, 4]-thiadiazin-5-yl)-2H-1-
benzopyran-2-ones on the anti-bacterial activity could not be
established owing to a mixed activity proﬁle for all derivatives.
Further, when anti-bacterial activity of some of the cou-
marinyl chalcones against B. subtilis, S. aureus, E. coli and
K. pneumoniae was performed (Jayashree et al., 2009), they
were found to be weak to moderately active as anti-bacterial,
however, the test compound 23d, a di-methoxy substituted 6-
chlorocoumarinyl chalcone showed activity as compared to
the standard streptomycin against all bacterial strains. This
scaffold from the coumarinyl chalcone series could be further
exploited to enhance and develop potential anti-bacterial
agents.
The preliminary screening of certain 3-coumarinoyl pyridi-
nium bromide 26a–l and 3-coumarinoyl quinolium bromide
derivatives 27a–c against B. subtilis, S. aureus, E. coli and P.
aeruginosa (Jayashree et al., 2010; Porwal et al., 2010), showed
that these compounds were either inactive or moderately active
as anti-bacterial on a few strains. The anti-bacterial sensitivity
of series of derivatives of 3-coumarinoyl pyridinium bromide
and 3-coumarinoyl quinolium bromide 26–27 against various
strains was found in order of; S. aureus> B. subtilis>
E. coli> P. aeruginosa as compared to the standard amoxicil-
lin and gentamycin, which were active against all the strains.
Thus, the preliminary screening revealed that such compounds
were better anti-bacterial agents against gram positive strains
as compared to gram negative organisms. Test compounds
such as 26a, 26c, 26d and 26i, bearing 6-chloro/H on thebenzopyrone ring showed better activity against all bacterial
strains as compared to the 6-bromo analogues and were further
selected for determination of MIC at 100 percent growth inhi-
bition. However, test compounds 26a and 26d were found to
be equally active as the standard amoxicillin against E. coli
and gentamycin against B. subtilis, respectively. Therefore, it
could be inferred that compounds 26a, 26c, 26d and 26i were
not potential enough against all bacterial strains when com-
pared to the standard gentamycin. Also, the quinolium bro-
mide derivatives of coumarin were less active as anti-
bacterial when compared to pyridinium bromide derivatives.
However, the same compounds did show greater anti-bacterial
activity against E. coli with MIC better than standard
amoxicillin.
Further, some of the substituted pyridinyl coumarins such
as 28b, 28d, 28f and 28g were also evaluated for their anti-bac-
terial activity. All compounds showed maximum activity
against B. subtilis, moderate against E. coli and minimum
against S. aureus as compared to standard gentamycin. Test
compounds such as 28b, 28f and 28g exhibited 100 percent
growth inhibition against B. subtilis at MIC value same as that
of the gentamycin. It was found that, all the four test com-
pounds were highly active against E. coli with MIC value bet-
ter than standard amoxicillin.
3.3. Miscellaneous
Evaluation of some of the salicylate derivatives 29–32 of cou-
marins for their anti-diabetic potential was attempted
(Jayashree et al., 2011) based on the rationale (Hogale et al.,
1987). When test compounds were screened for this activity
by in vitro non-enzymatic glycosylation of haemoglobin
method and by advanced glycation end product inhibition
method (Jedsadayanmata, 2005) using quercetin as standard,
the results showed that they were poor candidates for anti-dia-
betic activity.4. Physicochemical parameters
4.1. Hydrophobicity
Hydrophobicity is generally parameterised by partition coefﬁ-
cient (log p), determined by partitioning of a drug between
organic and aqueous phases. For our experiments, this physi-
cal constant was determined on some of the synthesised cou-
marin derivatives by the classical shake ﬂask method
(Sangster, 1989), using n-octanol/n-heptanol and phosphate
buffer (pH 7.4). Determination of log p for the series of com-
pounds such as 18–20 was carried out (Jayashree et al.,
2005a,b, 2006, 2007). Substitution of halogens at 6th position
on the parent compound 20a resulted in an increase in the par-
tition coefﬁcient, which was clearly evident as the correspond-
ing compounds such as 18a and 19a showed log p value in the
range of 1.27–1.41 as compared to that of the parent com-
pound at 1.18. The results also showed that triazolo thiadiaz-
inyl 6-bromo substituted coumarins were more hydrophobic
than their 6-chloro and 6-H counterparts. Substitution of the
hydroxy group irrespective of its positions in the ring led to
a decrease in the lipophilic character of compounds in the case
of 6-chloro/bromo/H series. Interestingly, para-methyl substi-
tuted compounds such as 18h and 20i with the highest partition
Coumarinyl heterocycles as useful therapeutic agents 891coefﬁcient among all did not possess any promising anti-bacte-
rial activity. However, compounds bearing the pyridinyl group
at para position, such as 18i, 19i and 20j, having optimum lipo-
philicity with log p in the range of 1.04–1.22, showed potent
anti-bacterial activity as compared to that of the standard
amoxicillin and gentamycin. Also, compounds bearing ortho,
para-dichlorophenoxy group such as 18k, 19k and 20l possessed
partition coefﬁcient in the range of 1.34–1.47 and were moder-
ately active as anti-bacterial. The compounds with minimum
log p such as 18d–e, 19d–e and 20e–f were least active against
bacterial strains. These ﬁndings helped in understanding the
effect of lipophilicity in terms of log p on the anti-bacterial
activity of triazolo thiadiazinyl coumarins. Further, com-
pounds with log p values above and below the optimum range
however, did not show any signiﬁcant biological activity. From
our study it was understood that, to develop a potentially use-
ful anti-bacterial agent using this scaffold, compounds should
bear at least an optimum log p value as seen in case of pyridinyl
substituted compounds.
To understand the pattern of lipophilic character of cou-
marinyl pyrazolines, few of the test compounds such as 24a,
24e, 24j, 25a and 25b were randomly selected (JayashreeFigure A.3 Synthesised amino co
Figure A.2 Synthesised coumarin-t
Figure A.1 Parent nucleus of coumarin.et al., 2008). Presence of an electronegative atom at the 6th
position of coumarin moiety in such studies greatly inﬂuenced
log p value. However, the average range of log p for bromo/
chloro and unsubstituted derivatives was found to be 0.08,
0.02 and 0.03, respectively. The increase in the lipophilicity
of coumarinyl pyrazolines was found to be in the order of:
bromo>chloroP unsubstituted compounds. A similar pattern
was also observed for compounds such as 25a and 25b.
Further, to clearly understand the effect of various substituted
coumarinyl pyrazolines on the partition coefﬁcient, some more
related studies may be required in future. Further, the partition
coefﬁcient of substituted pyridinyl and quinolium coumarin
derivatives was also studied (Jayashree et al., 2010). The log
p value of substituted pyridinyl coumarins varied with the
position of substituents on the pyridine ring. Compounds such
as 26a–c, bearing the para-ethoxy carbonyl group were less
lipophilic than their corresponding meta analogues 26d–f.
Alternatively, other derivatives bearing the para-methoxy
group, for example 26g–i possessed higher partition coefﬁcient
as compared to their corresponding meta derivatives 26j–l.
Further, in case of quinolium bromide salts of coumarin, com-
pounds 27b–c bearing halogen in form of the chloro/bromoumarin-thiazole Schiff’s bases.
hiazole carboxamide derivatives.
Figure A.4 Synthesised amino bromocoumarin-thiazole Schiff’s
bases.
Figure A.5 Synthesised amino chlorocoumarin-thiazole Schiff’s bases.
Figure A.6 Synthesised arylamino-bromocoumarin-thiazole derivatives.
Figure A.7 Synthesised triazolo-thiadiazinyl coumarin derivatives.
Figure A.8 Synthesised coumarinyl chalcones derivatives.
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Figure A.9 Synthesised pyrazoline-coumarin derivatives.
Figure A.10 Synthesised pyridine/quinoline-coumarin derivatives.
Figure A.11 Few other novel coumarin derivatives which were synthesised.
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Table B.1 Various coumarin derivatives synthesised and their physicochemical characteristics.
Code X R R1 R2 R3 Ar Yield (%) Melting
point (C)
1 - - - - - - 81 211
2a H - - - - - 82 240
2b p-NO2 - - - - - 74 263
2c m-NO2 - - - - - 75 250
2d o-NO2 - - - - - 69 180
2e o-Cl - - - - - 76 220
2f p-Cl - - - - - 78 285
2g m-Br - - - - - 63 275
2h p-Br - - - - - 59 266
2i o-Br - - - - - 61 218
2j m-Cl - - - - - 72 266
3 - - - - - - 77 265
4 - - - - - - 96 120
5 - - - - - - 76 162
6 - - - - - - 70 220
7a - H OCH3 OH H - 55 200
7b - NO2 H H H - 53 262
7c - H NO2 H H - 50 195
7d - H H N(CH3)2 H - 40 240
7e - H OCH3 OCH3 OCH3 - 42 185
7f - H OCH3 OCH3 H - 45 265
7g - OH H H H - 50 193
7h - CH3 H H H - 52 280
7i - H H Cl H - 55 284
7j - OH H H Br - 50 260
8 - - - - - - 58 146
9 - - - - - - 56 187
10a - H H Cl H - 62 255
10b - H OCH3 OCH3 OCH3 - 71 234
10c - NO2 H H H - 58 243
10d - H NO2 H H - 60 256
10e - H OCH3 OH H - 66 235
10f - OH H H Br - 66 276
10g - H H N(CH3)2 H - 69 180
10h - CH3 H H H - 64 218
10i - OH H H H - 68 224
10j - OCH3 H H H - 62 150
10k - H H H H - 78 225
10l - H OCH3 OCH3 H - 67 214
10m - H H NO2 H - 64 264
11 - - - - - - 88 235
12a - H H Cl H - 59 291
12b - H H H H - 73 251
12c - OH H H H - 62 289
12d - H H NO2 H - 68 282
12e - OCH3 OCH3 OCH3 H - 69 221
12f - H OCH3 OCH3 H - 68 217
12g - H OCH3 H H - 66 276
12h - OCH3 H H H - 70 204
12i - H H N(CH3)2 H - 78 218
12j - NO2 H H H - 65 262
12k - H NO2 H H - 67 289
12l - H Cl H H - 63 231
12m - Cl H H H - 67 247
13 - - - - - - 67 218
14 - - - - - - 61 211
15 Br - - - - - 94 220
16 Br - - - - - 80 205
17a H H - - - - 78 223
17b H C6H5 - - - - 77 204
894 B.S. Jayashree et al.
Table B.1 (continued)
Code X R R1 R2 R3 Ar Yield (%) Melting
point (C)
17c H o-ClC6H4 - - - - 67 282
17d H m-ClC6H4 - - - - 66 248
17e H p-ClC6H4 - - - - 76 225
17f H o-CH3C6H4 - - - - 58 248
17g H m-CH3C6H4 - - - - 72 215
17h H p-CH3C6H4 - - - - 75 233
17i H p-BrC6H4 - - - - 65 229
17j H p-FC6H4 - - - - 64 222
17k Br H - - - - 81 211
17l Br C6H5 - - - - 76 180
17m Br o-ClC6H4 - - - - 59 198
17n Br m-ClC6H4 - - - - 58 285
17o Br p-ClC6H4 - - - - 77 190
17p Br o-CH3C6H4 - - - - 65 265
17q Br m-CH3C6H4 - - - - 69 234
17r Br p-CH3C6H4 - - - - 72 194
17s Br p-BrC6H4 - - - - 63 280
17t Br p-FC6H4 - - - - 68 282
17u Br p-NO2C6H4 - - - - 64 190
18a - - - - - C6H4 65 252
18b - - - - - m-BrC6H4 66 242
18c - - - - - p-BrC6H4 69 246
18d - - - - - o-OHAC6H4 68 >294
18e - - - - - p-OHAC6H4 72 >294
18f - - - - - o-ClC6H4 70 272
18g - - - - - p-ClC6H4 70 276
18h - - - - - p-CH3AC6H4 66 242
18i - - - - - p-Pyridyl 65 250
18j - - - - - p-Chlorophenoxy 67 222
18k - - - - - o,p-Dichlorophenoxy 71 240
19a - - - - - C6H4 62 224
19b - - - - - m-BrC6H4 65 230
19c - - - - - p-BrC6H4 61 280
19d - - - - - m-OHAC6H4 60 >294
19e - - - - - p-OHAC6H4 68 >294
19f - - - - - o-ClC6H4 72 264
19g - - - - - p-ClC6H4 70 270
19h - - - - - p-CH3AC6H4 66 230
19i - - - - - p-pyridyl 65 232
19j - - - - - p-chlorophenoxy 67 210
19k - - - - - o,p-dichlorophenoxy 71 220
20a - - - - - AC6H4 62 218
20b - - - - - ACH2AC6H4 65 196
20c - - - - - m-BrC6H3 65 208
20d - - - - - p-BrC6H3 67 274
20e - - - - - o-OHAC6H4 68 >294
20f - - - - - p-OHAC6H4 66 >294
20g - - - - - o-ClC6H4 70 240
20h - - - - - p-ClC6H4 70 276
20i - - - - - p-CH3AC6H4 66 230
20j - - - - - p-pyridyl 65 230
20k - - - - - p-chlorophenoxy 62 196
20l - - - - - o,p-dichlorophenoxy 71 212
21a H H H N(CH3)2 H - 42 –
21b H Cl H H H - 36 282
21c H H H OCH3 H - 36 213
21d H H OCH3 OCH3 OCH3 - 45 –
21e Br H H N(CH3)2 H - 35 –
21f Br Cl H H H - 40 218
21g Br H H H H - 38 218
21h Br OH H H Br - 37 –
(continued on next page)
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Table B.1 (continued)
Code X R R1 R2 R3 Ar Yield (%) Melting
point (C)
21i Br H OCH3 OCH3 OCH3 - 41 –
21j Cl H H N(CH3)2 H - 37 –
21k Cl Cl H H H - 35 217
21l Cl H H OCH3 H - 43 –
21m Cl H OCH3 OCH3 OCH3 - 42 –
22a H H H H H - 35 164
22b Br H H H H - 34 –
22c Cl H H H H - 36 –
23a H C6H5 - - - - – 262
23b H m-CH3C6H4 - - - - – 240
23c H p-CH3C6H4 - - - - – 222
23d Cl m, p-(OCH3)2C6H3 - - - - – 242
23e Br CH‚CHAC6H3A[(OCH3)2 m,p] - - - - – 212
23f Br CH‚CHAC6H4 (p-OCH3) - - - - – 247
24a H H H N(CH3)2 H - 43 160
24b H Cl H H H - 38 155
24c H H H OCH3 H - 40 198
24d H H OCH3 OCH3 OCH3 - 35 184
24e Br H H N(CH3)2 H - 45 162
24f Br Cl H H H - 45 160
24g Br H H H H - 45 162
24h Br H H H Br - 42 172
24i Br H OCH3 OCH3 OCH3 - 40 180
24j Cl H H N(CH3)2 H - 40 180
24k Cl Cl H H H - 45 160
24l Cl H H OCH3 H - 50 165
24m Cl H OCH3 OCH3 OCH3 - 50 135
25a H H H H H - 42 174
25b Br H H H H - 40 164
25c Cl H H H H - 44 167
26a H p-COOC2H5 - - - - 85 210
26b Br p-COOC2H5 - - - - 75 228
26c Cl p-COOC2H5 - - - - 78 220
26d H m-COOC2H5 - - - - 75 224
26e Br m-COOC2H5 - - - - 79 225
26f Cl m-COOC2H5 - - - - 82 226
26g H p-COOCH3 - - - - 83 200
26h Br p-COOCH3 - - - - 78 208
26i Cl p-COOCH3 - - - - 82 218
26j H m-COOCH3 - - - - 79 218
26k Br m-COOCH3 - - - - 83 221
26l Cl m-COOCH3 - - - - 76 227
27a H - - - - - 79 230
27b Br - - - - - 76 219
27c Cl - - - - - 75 220
28a H - - - C6H5 - 62 188
28b Br - - - C6H5 - 62.5 190
28c Cl - - - C6H5 - 72.3 191
28d H - - - C6H4A(20-Cl) - 65 191
28e Br - - - C6H4A(20-Cl) - 55 191
28f Cl - - - C6H4A(20-Cl) - 73 200
28g H - H H Furfuryl - 56.5 189
29a - AOOCAC6H4 - - - - 88 210
29b - AOOCAC6H3A5Cl,2OH - - - - 86 238
30a - - - - - - 56 220
30b - AOCAC6H3A5NH2,2OH - - - - 78 >300
31a - AOOCAC6H4 - - - - 91 224
31b - AOOCAC6H3A5Cl,2OH - - - - 79 256
32a - AOOCAC6H4 - - - - 84 238
32b - AOOCAC6H3A5Cl,2OH - - - - 71 246
–, not found.
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higher log p as compared to the unsubstituted derivative 27a.
The presence of the chloro substituted phenyl group at the
4th position in the pyridine ring of the derivatives like 28d–f,
led to an increase in the log p value of the corresponding 4th
position unsubstituted derivatives 28a–c. However, when the
biological activity was correlated with partition coefﬁcient of
these derivatives, it was found that the derivative 26e with
highest log p was inactive against all bacterial strains tested.
On the other hand, it was noted that most of derivatives with
quinolium bromide salts of coumarins with optimum log p
range of 1.10–1.41, were moderately active as anti-bacterial.
From the results, it could be understood that substitution
of electronegative atom in form of halogens such as the
chloro/bromo group at the 6th position of the coumarin
nucleus leads to an increase in the partition coefﬁcient of the
parent/unsubstituted compound. It was also realised that,
compounds possessing an optimum balance of lipophilic and
hydrophilic characters were biologically active when compared
to the standards.
4.2. Other parameters
We wanted to understand the effect of substituents on few
other important physicochemical properties such as determina-
tion of dissociation constant in terms of pKa value. The disso-
ciation constant of both acidic and basic drug is governed by
pKa. The lower the pKa of an acidic drug, the stronger will
be the acid. Whereas, the higher the pKa of a basic drug, the
stronger will be the base. To have better understanding, one
such study was performed (Jayashree et al., 2010) where, esti-
mation of pKa of the substituted pyridinyl coumarin deriva-
tives was done. It was observed that compounds, including
the bromide salts 26–28, were in the range of 6–6.5, showing
moderate to weak basic character. Such compounds would
get ionised in the acidic pH as in case of gastric pH, but they
remain relatively unionised at intestinal pH, thereby showing
better absorption from the intestine. It was also observed that
substitution of different groups on the coumarin nucleus did
not bring any noticeable change in their dissociation constant
value. However, there is a need for further investigation to
determine pKa of other substituted coumarins.
5. Conclusion
In this review, an earnest attempt has been made to consoli-
date and highlight important research ﬁndings in the area of
coumarin for last nearly one decade. Emphasis has been made
in particular, on the synthetic routes undertaken for arriving at
substituted coumarinyl derivatives that have inﬂuenced their
pharmacological activities. Additionally, some of the impor-
tant physicochemical parameters ﬁxed for the coumarinyl
derivatives are also being furnished. Earlier work on couma-
rins was mostly related to their isolation, characterisation
and exploiting their biological activities from the natural
sources, until recently attempts were made in the area of syn-
thetic coumarins useful as potentially biologically active com-
pounds. This review therefore, will provide a better insight to
researchers on the potential biologically useful substituted cou-
marinyl derivatives as intermediates for achieving coumarin
analogues with high therapeutic value. Furthermore, it willhelp in understanding the effect of various substituents on
the biological as well as the physicochemical characteristics
of such coumarinyl compounds.
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